Drug Trial Radar · NCT00706147
Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis
Last checked: Nov 19, 2026Latest source record: Jan 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jan 2009
Primary completion
Dec 2014
Study completion Nov 2016
Sponsor
- Lead sponsor
- University of MiamiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Massachusetts General Hospital
- First posted
- Jun 27, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study will be to demonstrate the safety, tolerability, and efficacy of arimoclomol in subjects with SOD1 positive familial Amyotrophic Lateral Sclerosis (ALS). This type of ALS is HEREDITARY (runs in families), and at least one other person in the family must have had ALS. Study hypotheses: Arimoclomol, taken at a dose of 200 mg three times daily will improve survival as defined by time to death, tracheostomy or permanent assisted ventilation. In addition, it will be safe and well tolerated in subjects with SOD1 positive familial ALS. Funding Source - FDA-OOPD
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
ArimoclomolDrug
Drug: Arimoclomol capsules given three times per day
PlaceboDrug
Drug: Placebo capsules given three times per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to death, tracheostomy or permanent assisted ventilation will be the primary outcome measure.Time frame: 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Miami Miller School of Medicine
Miami, Florida
Massachusetts General Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.